<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Serina Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/serina-therapeutics-inc</link>
<description>Latest news and press releases for Serina Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 10:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/serina-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d782e651cc36e47534293e.webp</url>
<title>Serina Therapeutics, Inc.</title>
<link>https://6ix.com/company/serina-therapeutics-inc</link>
</image>
<item>
<title>Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-to-present-at-the-5th-lnp-formulation-and-process-development-summit</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-to-present-at-the-5th-lnp-formulation-and-process-development-summit</guid>
<pubDate>Tue, 07 Apr 2026 10:00:00 GMT</pubDate>
<description>– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucleotide payloads – HUNTSVILLE, AL, April 07, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Serina T</description>
</item>
<item>
<title>Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-nyse-american-acceptance-of-continued-listing-compliance-plan</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-nyse-american-acceptance-of-continued-listing-compliance-plan</guid>
<pubDate>Thu, 02 Apr 2026 20:13:00 GMT</pubDate>
<description>HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported that the NYSE American LLC ("NYSE American") has accepted the Company’s business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) or 1003(a)(ii) of the NYSE American Company Guide. "We are pleased that NYS</description>
</item>
<item>
<title>Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-reports-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-reports-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Wed, 25 Mar 2026 20:20:00 GMT</pubDate>
<description>- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year w</description>
</item>
<item>
<title>Serina Therapeutics to Present at the 38th Annual Roth Conference</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-to-present-at-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-to-present-at-the-38th-annual-roth-conference</guid>
<pubDate>Tue, 24 Mar 2026 10:00:00 GMT</pubDate>
<description>HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026, at 11:30 a.m. PST. A live webcast of the fireside chat style presentation will be accessible to registered attendees at th</description>
</item>
<item>
<title>Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-secures-up-to-dollar30-million-in-private-placement-to-advance-registrational-trial-of-ser-252-for-advanced-parkinsons-disease</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-secures-up-to-dollar30-million-in-private-placement-to-advance-registrational-trial-of-ser-252-for-advanced-parkinsons-disease</guid>
<pubDate>Wed, 18 Mar 2026 20:10:00 GMT</pubDate>
<description>- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at $2.25 per share, representing a 68% premium to the March 17, 2026 closing price– - Financing includes 50% warrant coverage priced at $5 per share, representing a 273% premium to market, if exercised would raise up to an additional $33.3 million, extending runway into 2H 2027 - - P</description>
</item>
<item>
<title>Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-dosing-of-first-patient-in-phase-1b-registrational-trial-of-ser-252-for-advanced-parkinsons-disease</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-dosing-of-first-patient-in-phase-1b-registrational-trial-of-ser-252-for-advanced-parkinsons-disease</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform™ - HUNTSVILLE, AL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ d</description>
</item>
<item>
<title>Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-first-patient-enrolled-in-phase-1b-registrational-trial-of-ser-252-for-advanced-parkinsons-disease</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-first-patient-enrolled-in-phase-1b-registrational-trial-of-ser-252-for-advanced-parkinsons-disease</guid>
<pubDate>Thu, 19 Feb 2026 11:00:00 GMT</pubDate>
<description>- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for first patient dosing in the first quarter of 2026 HUNTSVILLE, AL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization t</description>
</item>
<item>
<title>Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-fda-clearance-of-ind-application-for-ser-252-for-the-treatment-of-advanced-parkinsons-disease</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-fda-clearance-of-ind-application-for-ser-252-for-the-treatment-of-advanced-parkinsons-disease</guid>
<pubDate>Wed, 28 Jan 2026 21:12:00 GMT</pubDate>
<description>- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ PlatformTM drug optimization technology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (I</description>
</item>
<item>
<title>Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-receives-nyse-deficiency-notification-regarding-shareholders-equity</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-receives-nyse-deficiency-notification-regarding-shareholders-equity</guid>
<pubDate>Thu, 15 Jan 2026 21:30:00 GMT</pubDate>
<description>HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, received a notice from the New York Stock Exchange ("NYSE") that it is below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE's list</description>
</item>
<item>
<title>Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-strengthens-leadership-team-with-appointment-of-dr-joshua-thomas-as-vp-head-of-chemistry</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-strengthens-leadership-team-with-appointment-of-dr-joshua-thomas-as-vp-head-of-chemistry</guid>
<pubDate>Thu, 11 Dec 2025 21:15:00 GMT</pubDate>
<description>HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to opti</description>
</item>
<item>
<title>Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-submits-complete-response-to-fda-clinical-hold-letter-for-ser-252-program</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-submits-complete-response-to-fda-clinical-hold-letter-for-ser-252-program</guid>
<pubDate>Wed, 10 Dec 2025 21:30:00 GMT</pubDate>
<description>– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback HUNTSVILLE, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprie</description>
</item>
<item>
<title>Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-highlights</guid>
<pubDate>Thu, 13 Nov 2025 11:10:00 GMT</pubDate>
<description>HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2025, along with key recent updates. Steve Ledger, Chief Executive Officer of Seri</description>
</item>
<item>
<title>Serina Therapeutics Provides Regulatory Update on SER-252 Program</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-provides-regulatory-update-on-ser-252-program</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-provides-regulatory-update-on-ser-252-program</guid>
<pubDate>Mon, 03 Nov 2025 11:05:00 GMT</pubDate>
<description>- FDA requests additional information on a formulation component - HUNTSVILLE, AL, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company’s Investigational New Drug (IND) application for SER-252, Serina’s lead development program for advanced Pa</description>
</item>
<item>
<title>Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-launches-enhanced-corporate-communications-platform-to-strengthen-engagement-with-patients-clinicians-and-investors</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-launches-enhanced-corporate-communications-platform-to-strengthen-engagement-with-patients-clinicians-and-investors</guid>
<pubDate>Wed, 08 Oct 2025 15:00:00 GMT</pubDate>
<description>HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community. The new initiative expands Serina’s direct channels of communication to provid</description>
</item>
<item>
<title>Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-draws-first-dollar5-million-funding-tranche-to-support-registrational-trial-of-ser-252-in-parkinsons-disease</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-draws-first-dollar5-million-funding-tranche-to-support-registrational-trial-of-ser-252-in-parkinsons-disease</guid>
<pubDate>Mon, 06 Oct 2025 20:15:00 GMT</pubDate>
<description>$5 million tranche received under up to $20 million financing agreementIND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the drawdown of the first $5 million tranche from its previously announced financing agreement, w</description>
</item>
<item>
<title>Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-secures-up-to-dollar20-million-to-advance-registrational-trial-of-ser-252-in-parkinsons-disease</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-secures-up-to-dollar20-million-to-advance-registrational-trial-of-ser-252-in-parkinsons-disease</guid>
<pubDate>Tue, 09 Sep 2025 19:20:00 GMT</pubDate>
<description>Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic equity and non-dilutive alternatives HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that it ha</description>
</item>
<item>
<title>Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</guid>
<pubDate>Mon, 08 Sep 2025 10:00:00 GMT</pubDate>
<description>HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY on September 8, 2025, at 9:30 a.m. ET. A live webcast of the presentation will be accessible to registered attendees at this link. An</description>
</item>
<item>
<title>Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-fda-feedback-supports-registrational-trial-design-of-ser-252-in-advanced-parkinsons-disease-under-505b2-nda-pathway</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-announces-fda-feedback-supports-registrational-trial-design-of-ser-252-in-advanced-parkinsons-disease-under-505b2-nda-pathway</guid>
<pubDate>Mon, 25 Aug 2025 20:15:00 GMT</pubDate>
<description>- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that following a recent Type B meeting with the U.S. Food and Drug Administration (FDA), the FDA’s written feedback su</description>
</item>
<item>
<title>Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-highlights</guid>
<pubDate>Mon, 11 Aug 2025 20:30:00 GMT</pubDate>
<description>HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. “We’re proud of the momentum we’ve built across our development programs. With SER-252 on track</description>
</item>
<item>
<title>Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)</title>
<link>https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-advances-poz-vmat2i-into-development-for-tardive-dyskinesia-td</link>
<guid isPermaLink="true">https://6ix.com/company/serina-therapeutics-inc/news/serina-therapeutics-advances-poz-vmat2i-into-development-for-tardive-dyskinesia-td</guid>
<pubDate>Tue, 29 Jul 2025 10:44:00 GMT</pubDate>
<description>- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 therapy - HUNTSVILLE, AL, July 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the advancement of i</description>
</item>
</channel>
</rss>